Share: New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (September 15-19) shows that some individuals who are taking Ozempic, Wegovy or Mounjaro find that foods taste sweeter or saltier than before
Patients typically lose 10-15% of their body weight, with some achieving even greater losses
Many patients find that fatigue diminishes over time as their body acclimates to the medication
These findings also confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health." A new European consortium known as Sophia (Stratification of Obese Phenotypes to Optimize Future Obesity Therapy), led by scientists at University College Dublin, is now attempting to investigate this in more detail
Therefore, we found that the enhanced insulinotropic effect of exendin-phe1 in vitro is recapitulated in a mouse model of T2D, suggesting that GLP-1R trafficking plays a role in determining the responses to therapeutic GLP-1R agonists in vivo
%201.png)
